New HIV capsid inhibitors show promise in early trial
NCT ID NCT06039579
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 28 times
Summary
This study tested two experimental oral medications (VH4004280 and VH4011499) in 44 adults with HIV who had never taken HIV drugs before. The goal was to see how well these drugs lower the amount of virus in the blood over 10 days. The study also checked for side effects. These drugs are not a cure, but they may offer a new way to control HIV.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
GSK Investigational Site
Bakersfield, California, 93301, United States
-
GSK Investigational Site
DeLand, Florida, 32720, United States
-
GSK Investigational Site
Newark, New Jersey, 07102, United States
-
GSK Investigational Site
Buenos Aires, 1023, Argentina
-
GSK Investigational Site
Buenos Aires, C1202ABB, Argentina
-
GSK Investigational Site
Buenos Aires, C1425AGC, Argentina
-
GSK Investigational Site
Ciudad Autonoma de Bueno, C1405CKC, Argentina
-
GSK Investigational Site
Montreal, Quebec, H2L 4P9, Canada
-
GSK Investigational Site
Marseille, 13003, France
-
GSK Investigational Site
Nantes, 44093, France
-
GSK Investigational Site
Paris, 75018, France
-
GSK Investigational Site
Cologne, 50937, Germany
-
GSK Investigational Site
Milan, 20157, Italy
-
GSK Investigational Site
Guadalajara, 44160, Mexico
-
GSK Investigational Site
Mexico City, 06760, Mexico
-
GSK Investigational Site
Barcelona, 08907, Spain
-
GSK Investigational Site
Barcelona, 08916, Spain
-
GSK Investigational Site
Madrid, 28034, Spain
-
GSK Investigational Site
Madrid, 28046, Spain
-
GSK Investigational Site
London, SE5 8RX, United Kingdom
Conditions
Explore the condition pages connected to this study.